Success Metrics

Clinical Success Rate
100.0%

Based on 16 completed trials

Completion Rate
100%(16/16)
Active Trials
13(38%)
Results Posted
131%(21 trials)

Phase Distribution

Ph phase_1
16
47%
Ph phase_2
10
29%
Ph early_phase_1
1
3%
Ph phase_4
1
3%
Ph phase_3
3
9%

Phase Distribution

17

Early Stage

10

Mid Stage

4

Late Stage

Phase Distribution31 total trials
Early Phase 1First-in-human
1(3.2%)
Phase 1Safety & dosage
16(51.6%)
Phase 2Efficacy & side effects
10(32.3%)
Phase 3Large-scale testing
3(9.7%)
Phase 4Post-market surveillance
1(3.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

94.1%

16 of 17 finished

Non-Completion Rate

5.9%

1 ended early

Currently Active

13

trials recruiting

Total Trials

34

all time

Status Distribution
Active(15)
Completed(16)
Terminated(1)
Other(2)

Detailed Status

Completed16
Active, not recruiting10
Recruiting3
unknown2
Not yet recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
34
Active
13
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (3.2%)
Phase 116 (51.6%)
Phase 210 (32.3%)
Phase 33 (9.7%)
Phase 41 (3.2%)

Trials by Status

active_not_recruiting1029%
recruiting39%
unknown26%
completed1647%
not_yet_recruiting26%
withdrawn13%

Recent Activity

13 active trials
Showing 5 of 34
active_not_recruitingphase_2

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620
active_not_recruitingphase_2

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04320888
active_not_recruitingphase_2

A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

NCT04280081
completed

Selpercatinib and Body Composition

NCT07543887
active_not_recruitingphase_2

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

NCT04268550
View all 34 trials

Clinical Trials (34)

Showing 20 of 34 trialsScroll for more
NCT03155620Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Active Not Recruiting
NCT04320888Phase 2

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Active Not Recruiting
NCT04280081Phase 2

A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

Active Not Recruiting
NCT07543887

Selpercatinib and Body Composition

Completed
NCT04268550Phase 2

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

Active Not Recruiting
NCT04211337Phase 3

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active Not Recruiting
NCT04819100Phase 3

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Active Not Recruiting
NCT07146893Early Phase 1

Feasibility Study for Repurposing RET Inhibitors

Not Yet Recruiting
NCT03899792Phase 1

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Active Not Recruiting
NCT05469113Phase 1

A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants

Completed
NCT04759911Phase 2

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Active Not Recruiting
NCT04194944Phase 3

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Active Not Recruiting
NCT05338476Phase 1

A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants

Completed
NCT05338489Phase 1

A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants

Completed
NCT05468164Phase 1

A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants

Completed
NCT05469100Phase 1

A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function

Completed
NCT05630274Phase 1

A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants

Completed
NCT05906836Phase 1

A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants

Completed
NCT07010393Phase 4

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

Not Yet Recruiting
NCT05338515Phase 1

A Study of Selpercatinib (LY3527723) in Healthy Participants

Completed

Drug Details

Intervention Type
DRUG
Total Trials
34